Clinical Testing News and Research

RSS

Endocyte announces results from study of EC145 in patients with advanced non-small cell lung cancer

Results were presented at the 13th World Conference on Lung Cancer in San Francisco. The single arm Phase II study evaluated the therapeutic agent EC145 and the molecular imaging agent EC20 in 42 patients with advanced adenocarcinoma of the lung. Forty percent of patients involved in the clinical trial had already failed at least four chemotherapy regimens prior to enrollment in the study.

12 Aug 2009

Ichor Medical Systems awarded $3.3 million to develop Alzheimer’s vaccine

Ichor Medical Systems of San Diego has announced that it has been selected to receive a $3.3 million grant award from the National Institute of Neurological Disorders and Stroke (NINDS) for development of a vaccine for Alzheimer’s disease.

6 Aug 2009

NIAID to launch 2009 H1N1 influenza vaccine trials

Scientists in a network of medical research institutions across the United States are set to begin a series of clinical trials to gather critical data about influenza vaccines, including two candidate H1N1 flu vaccines. The research will be under the direction of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

22 Jul 2009

Recent releases: HIV prevention; clinical trials debate; definition of global health; drug resistant tuberculosis

In a Journal of the American Medical Association commentary piece, Anthony Fauci and Carl Dieffenbach of the National Institute of Allergy and Infectious Diseases explore results from a WHO mathematical model study that found universal, voluntary, annual HIV testing followed up with immediate treatment for those testing positive -- the "test and treat model" -- could "reduce HIV incidence" and "end the [HIV] pandemic within 50 years."

13 Jun 2009

Study shows promise for new cancer-stopping therapy

Researchers at Nationwide Children's Hospital and Johns Hopkins University have discovered that delivering a small molecule that is highly expressed in normal tissues but lost in diseased cells can result in tumor suppression.

12 Jun 2009

Active ingredient in green tea shows promise in leukemia trials

Mayo Clinic researchers are reporting positive results in early leukemia clinical trials using the chemical epigallocatechin gallate (EGCG), an active ingredient in green tea.

26 May 2009

Researchers unlock mystery of potentially fatal reaction to smallpox vaccine

Researchers from the La Jolla Institute for Allergy & Immunology have pinpointed the cellular defect that increases the likelihood, among eczema sufferers, of developing eczema vaccinatum, a severe and potentially fatal reaction to the smallpox vaccine.

25 May 2009

NIH to develop therapeutics for rare and neglected diseases

The National Institutes of Health is launching the first integrated, drug development pipeline to produce new treatments for rare and neglected diseases. The $24 million program jumpstarts a trans-NIH initiative called the Therapeutics for Rare and Neglected Diseases program, or TRND.

20 May 2009

New kind of treatment for sexually transmitted diseases

Yale researchers describe a breakthrough in safe and effective administration of potential antiviral drugs - small interfering RNA (siRNA) molecules that silence genes - the first step in development of a new kind of treatment for sexually transmitted diseases (STDs). The work is reported May 4 as an advance online publication of Nature Materials.

3 May 2009

New cancer centre launched in Southampton

Southampton joins a unique chain of Cancer Research UK Centres that are being launched across the UK.

29 Apr 2009

Stem cell therapy used to restore transparency in corneas

Stem cells collected from human corneas restore transparency and don't trigger a rejection response when injected into eyes that are scarred and hazy, according to experiments conducted in mice by researchers at the University of Pittsburgh School of Medicine.

12 Apr 2009

FDA provides positive review of InNexus Biotechnology development plan for lead preclinical candidate

InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).

2 Apr 2009

New TB vaccine developed using a genetically modified adenovirus

McMaster University researchers are about to launch Canada's first tuberculosis (TB) vaccine clinical trial with a vaccine totally designed, manufactured and tested within McMaster.

20 Mar 2009

Synthesizing Vernix caseosa

Even after nine months soaking in the womb, a newborn's skin is smooth - unlike an adult's in the bath.

17 Mar 2009

Immune cells play surprising role in cystic fibrosis lung damage

Immune cells once thought to be innocent bystanders in cystic fibrosis may hold the key to stopping patients' fatal lung disease.

16 Mar 2009

Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies

A class of Alzheimer's disease drugs currently studied in clinical trials appears to reduce damage caused by traumatic brain injury in animals, researchers at Georgetown University Medical Center report in an upcoming advance online publication of Nature Medicine.

15 Mar 2009